DOI: http://dx.doi.org/10.18203/2349-2902.isj20194070

Impact of the modified bleomycin, etoposide and cisplatinum chemotherapy regimen on the outcome of testicular germ cell tumor: a tertiary care institute experience

Renu Madan, Niketa Thakur, Sakshi Rana, Narendra Kumar, Budhi Singh Yadav, Divya Khosla, Rakesh Kapoor

Abstract


Background: Bleomycin, cisplatin and etoposide (BEP) based combination chemotherapy is established as standard treatment for testicular germ cell tumors. As these tumors are highly curable, so management is crucial in terms of long-term toxicity particularly lung toxicity. With standard BEP there is increased toxicity which leads to poor compliance. So, we at a tertiary care center assessed modified BEP regimen in such patients and evaluated its effectiveness in terms of response and toxicity as compared to standard BEP.

Methods: Forty-nine patients of testicular germ cell tumors were enrolled in this study from January 2012 to December 2016. The modified BEP regimen consisted of bleomycin 30 IU day 1, cisplatin 20 mg/m2 day 1-5 and etoposide 100 mg/m2 day 1 to 5, given every three weeks. The planned drug intensities were 33.3 mg/m2/week for cisplatin, 166.7 mg/m2 week for etoposide and 10 IU/body/week for bleomycin. The schedule for chemotherapy was as follows: four courses of modified BEP for stage I patients and six courses of modified BEP for stage I S, II and III patients.

Results: Overall response rate in our study was seen to be 81.2% which was comparable with the available evidence. Five (10.4%) patients developed febrile neutropenia. Two (4.1%) patients showed clinically evident bleomycin induced pulmonary toxicity. Lower toxicity seen in these patients led to better overall compliance.

Conclusions: Modified BEP protocol is a good alternative to standard BEP with comparable efficacy and reduced toxicity. 


Keywords


Testicular germ cell tumors, Febrile neutropenia, Modified BEP

Full Text:

PDF

References


Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–36.

Einhorn LH, Donohue J. Cis-diamminedi-chloroplatinum. vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977:87:293-8.

Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity. Eur J Cancer. 1992;28:86–91.

Miyanaga N, Akaza H, Hattori K, Takeshima H, Koiso K. The importance of dose intensity in chemotherapy of advanced testicular cancer. Urol Int. 1995;54:220–5.

Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316:1435–40.

Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol. 2000;18:2413–8.

Kantolf PW, Kalish LA, McDowell-Bryant P, Canellos GP, Gibbs R, Richie JP, et al: Long-term follow-up of 150 patients with testicular cancer treated at a single institution. J Urol. 1992:147:82-8.

Oliver RID, Dhaliwal HS, Hope-Stone HF, Blandy JP. Short-course etoposide. bleomycin and cisplatin in the treatment of metastatic germ cell tumors: Appraisal of its potential as adjuvant chemotherapy for stage I testis tumours. Br J Urol. 1988:61:53-8.

Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, et al. Filgrastim during combination chemotherapy of patients with poor prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol. 1998;16:716–24.

Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 1995;13:470–6.

Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991–95: a review of patients with germ cell tumours. Br J Cancer. 1998;78:1061–6.

Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120:617–24.

Kawai K, Hinotsu S, Tomobe M, Akaza H, et al. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin induced pulmonary toxicity. Jpn J Clin Oncol. 1998;28:546–50.

Hryniuk WM, Figueredo A, Goodyear M. Applications of dose intensity to problems in chemotherapy. Semin Oncol. 1987;14:3-11.